Fly News Breaks for May 16, 2016
May 16, 2016 | 14:21 EDT
Wedbush analyst David Nierengarten earlier today downgraded Anacor Pharmaceuticals to Neutral after the company agreed to be acquired by Pfizer. The analyst has a $99.25 price target for the shares.
News For ANAC;PFE From the Last 2 Days